Quick answer: R3TA Research Peptide – 10 mg / 20 mg is presented by Nexigen as a research peptide for legitimate laboratory, analytical and scientific research. This page provides product-specific research context and links to related Nexigen research resources.
Research Peptides hub · Research guide · Related R3TA – / research
R3TA Research Peptide — Product Overview
R3TA is Nexigen Peptides’ research designation for
retatrutide (LY3437943), an investigational synthetic peptide
studied in research involving three receptor systems:
GIPR, GLP-1R and GCGR.
retatrutide (LY3437943), an investigational synthetic peptide
studied in research involving three receptor systems:
GIPR, GLP-1R and GCGR.
This triple-receptor profile distinguishes retatrutide from research compounds
focused on a single receptor pathway or dual-receptor system and makes the
compound relevant to laboratory investigations involving receptor pharmacology,
peptide signaling, multi-receptor interactions and comparative experimental
research.
focused on a single receptor pathway or dual-receptor system and makes the
compound relevant to laboratory investigations involving receptor pharmacology,
peptide signaling, multi-receptor interactions and comparative experimental
research.
Nexigen R3TA is available in
10 mg and 20 mg research formats and is supplied exclusively
for legitimate laboratory, analytical and scientific research.
10 mg and 20 mg research formats and is supplied exclusively
for legitimate laboratory, analytical and scientific research.
Research Material: R3TA / Retatrutide (LY3437943)
Available Quantities: 10 mg and 20 mg
Research Classification: Triple-receptor agonist peptide
Research Use: Laboratory, analytical and scientific research only
R3TA / Retatrutide Research Specifications
| Specification | Information |
|---|---|
| Research Material | R3TA |
| Scientific Identity | Retatrutide |
| Development Identifier | LY3437943 |
| CAS Number | 2381089-83-2 |
| Material Type | Synthetic research peptide |
| Receptor Systems | GIPR / GLP-1R / GCGR |
| Available Quantities | 10 mg / 20 mg |
| Brand | Nexigen Peptides |
| Analytical Documentation | Refer to current batch documentation |
| Intended Use | Laboratory research only |
What Is R3TA / Retatrutide?
Retatrutide, also identified in scientific literature as
LY3437943, is an investigational peptide studied in connection
with single-molecule multi-receptor agonism.
LY3437943, is an investigational peptide studied in connection
with single-molecule multi-receptor agonism.
Unlike research compounds focused principally on one receptor pathway,
retatrutide has been investigated for activity involving three distinct
receptor systems:
retatrutide has been investigated for activity involving three distinct
receptor systems:
- GIP receptor — GIPR
- GLP-1 receptor — GLP-1R
- Glucagon receptor — GCGR
This receptor profile makes retatrutide relevant to scientific investigations
involving receptor selectivity, signaling pathways, peptide pharmacology and
comparative multi-receptor research.
involving receptor selectivity, signaling pathways, peptide pharmacology and
comparative multi-receptor research.
R3TA Triple-Receptor Research
GIP Receptor — GIPR
The glucose-dependent insulinotropic polypeptide receptor belongs to the class B
family of G-protein-coupled receptors and is investigated extensively in
incretin-related and receptor-signaling research.
family of G-protein-coupled receptors and is investigated extensively in
incretin-related and receptor-signaling research.
GLP-1 Receptor — GLP-1R
The glucagon-like peptide-1 receptor is another class B
G-protein-coupled receptor examined extensively in peptide signaling,
receptor pharmacology and metabolic research.
G-protein-coupled receptor examined extensively in peptide signaling,
receptor pharmacology and metabolic research.
Glucagon Receptor — GCGR
The glucagon receptor represents the third receptor system associated with
retatrutide’s experimental pharmacological profile. Researchers may evaluate
GCGR-associated activity independently or within broader multi-receptor
experimental systems.
retatrutide’s experimental pharmacological profile. Researchers may evaluate
GCGR-associated activity independently or within broader multi-receptor
experimental systems.
Why Triple-Receptor Research Is Important
Multi-receptor peptide systems allow researchers to investigate experimental
questions that differ from those associated with conventional single-receptor
compounds.
questions that differ from those associated with conventional single-receptor
compounds.
Research involving R3TA / retatrutide may examine:
- Receptor selectivity — how a peptide interacts with different
receptor systems under defined experimental conditions. - Signal transduction — how receptor activation relates to
downstream cellular signaling. - Multi-receptor interactions — how multiple receptor pathways
behave when engaged by a single molecular research tool. - Comparative pharmacology — experimental differences between
single-, dual- and triple-receptor peptide systems. - Concentration-response relationships — how experimental
responses change across defined concentrations and assay conditions.
R3TA / Retatrutide Research Context
Retatrutide has been investigated in scientific studies examining its
multi-receptor pharmacology and experimental characteristics.
multi-receptor pharmacology and experimental characteristics.
Published research has evaluated LY3437943 as a compound with activity involving
the glucose-dependent insulinotropic polypeptide receptor, glucagon-like
peptide-1 receptor and glucagon receptor.
the glucose-dependent insulinotropic polypeptide receptor, glucagon-like
peptide-1 receptor and glucagon receptor.
Researchers comparing published findings should consider the specific study
population, experimental methodology, formulation, concentration and research
conditions used in each investigation.
population, experimental methodology, formulation, concentration and research
conditions used in each investigation.
Published findings concerning retatrutide itself should not be interpreted as
establishing performance characteristics or clinical properties of a specific
Nexigen production lot.
establishing performance characteristics or clinical properties of a specific
Nexigen production lot.
R3TA Mechanism of Action — Research Context
The experimental pharmacological profile of retatrutide centers on agonist
activity involving:
activity involving:
GIPR + GLP-1R + GCGR
In experimental systems, receptor agonists interact with corresponding receptor
targets and may initiate downstream signaling pathways.
targets and may initiate downstream signaling pathways.
Research involving retatrutide may therefore investigate:
- receptor activation profiles;
- intracellular signaling;
- concentration-response relationships;
- receptor selectivity;
- pathway interactions;
- comparative peptide pharmacology.
How Is R3TA Research Material Evaluated?
Peptide research materials may be characterized using complementary analytical
methods designed to investigate identity, composition and other
material-specific characteristics.
methods designed to investigate identity, composition and other
material-specific characteristics.
High-Performance Liquid Chromatography — HPLC
HPLC may be used to examine the chromatographic characteristics of a peptide
sample under defined analytical conditions.
sample under defined analytical conditions.
Liquid Chromatography–Mass Spectrometry — LC-MS
LC-MS combines chromatographic separation with mass-related detection and may
provide complementary information relevant to peptide identity and molecular
characterization.
provide complementary information relevant to peptide identity and molecular
characterization.
Mass Spectrometry
Mass-spectrometric techniques can provide molecular information useful when
evaluating whether detected material is consistent with the expected compound.
evaluating whether detected material is consistent with the expected compound.
Quantity / Content Analysis
Where performed, quantitative analytical methods may provide information
regarding the amount of material detected within an analyzed sample.
regarding the amount of material detected within an analyzed sample.
Why Batch-Specific Documentation Matters
A product name or generalized purity statement does not fully characterize an
individual production lot.
individual production lot.
Researchers evaluating R3TA should review available information including:
- lot or batch number;
- compound identity;
- nominal vial quantity;
- analytical methodology;
- reported analytical results;
- testing date;
- testing laboratory;
- available chromatographic or molecular information;
- supporting analytical documentation.
Review Current R3TA Documentation
Researchers should review currently available analytical documentation
associated with the applicable Nexigen production lot.
Laboratory Handling and Storage
Handling, preparation and storage requirements depend on the material form,
analytical method and laboratory protocol.
analytical method and laboratory protocol.
Laboratory personnel should follow validated procedures and applicable
material-specific stability information where available.
material-specific stability information where available.
Researchers should minimize unnecessary exposure to:
- moisture;
- excessive heat;
- direct light;
- uncontrolled temperature fluctuations;
- environmental contamination.
Nexigen does not provide human or veterinary preparation, dosing, injection or
administration instructions.
administration instructions.
R3TA / Retatrutide Research Resources
R3TA / Retatrutide Research Peptide
Nexigen Research Library
R3TA Batch Documentation
Nexigen Research Materials
Reference Resources
R3TA / Retatrutide Research FAQ
What is R3TA?
R3TA is Nexigen Peptides’ research designation for
retatrutide, also identified in scientific literature as
LY3437943.
retatrutide, also identified in scientific literature as
LY3437943.
What type of research peptide is retatrutide?
Retatrutide is studied as a multi-receptor peptide involving
GIPR, GLP-1R and GCGR.
GIPR, GLP-1R and GCGR.
What is the CAS number associated with retatrutide?
The CAS number associated with retatrutide is
2381089-83-2.
2381089-83-2.
What quantities of R3TA does Nexigen offer?
Nexigen R3TA is currently available in
10 mg and 20 mg research formats.
10 mg and 20 mg research formats.
Why is retatrutide described as a triple-receptor agonist?
The designation refers to experimental activity involving the GIP receptor,
GLP-1 receptor and glucagon receptor within a single research compound.
GLP-1 receptor and glucagon receptor within a single research compound.
Does Nexigen provide R3TA batch documentation?
Researchers should review the currently available batch-specific analytical
documentation associated with the applicable Nexigen production lot.
documentation associated with the applicable Nexigen production lot.
How should R3TA research material be stored?
Researchers should follow the storage information provided on the current
Nexigen product label and applicable product and batch documentation.
Nexigen product label and applicable product and batch documentation.
Is Nexigen R3TA intended for human use?
No. Nexigen R3TA is supplied exclusively for legitimate laboratory,
analytical and scientific research and is
not intended for human or veterinary use or consumption.
analytical and scientific research and is
not intended for human or veterinary use or consumption.
Research Use Only
Nexigen supplies this material exclusively for legitimate laboratory,
analytical and scientific research. It is not intended for human or veterinary
use or consumption. Nexigen does not provide medical advice, dosing
recommendations or personal-use guidance.
R3TA – / Research at a Glance
Quick Answer
R3TA Research Peptide – 10 mg / 20 mg is presented by Nexigen as a research peptide for legitimate laboratory, analytical and scientific research.
Key Facts
- Research material: R3TA – /
- Page type: Product-specific research material page
- Related research resources: 5
- Aliases/search terms: r3ta, retatrutide
Evidence Interpretation
Research findings linked from this page may come from biochemical, cellular, animal or human studies depending on the compound. Those evidence levels answer different questions and should not be treated as interchangeable.
What This Page Does Not Establish
This page does not establish human or veterinary safety, efficacy, dosing, administration or a clinical indication. Nexigen does not provide personal-use guidance.
